设为首页         
  
首 页 学术动态   最新资讯   会议专题 学术幻灯 专家访谈 精彩视频 病例讨论 循证指南 积分商城 名家讲堂
当前位置:眼科首页>(ARVO)美国眼科和视觉研究协会年会>正文
[ARVO2012]ESASO的学术委员会主席Francesco Bandello教授专访

玻璃体视网膜  作者:  FrancescoBandello  2012/5/14 16:03:00
国际眼科时讯版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。
内容概要:Dr Bandello: LUMINOUS是一项流行病学研究,我们的目标是对所有不同雷珠单抗适应证且接受过雷珠单抗治疗的患者进行登记。理想中,所有接受雷珠单抗治疗的患者全部进行登记。当然,这是一项很难达到的目标,但是我们将会登记尽可能多的患者。这一项目在不同大洲均在进行,我们在世界上许多地方设有研究中心

  <International OphthalmologyTimes>: Can you give us a brief introduction to your study?
  Dr Bandello: The LUMINOUS is an epidemiologic study which is aimed at registering all patients treated with ranibizumab for different kinds of indications. Ideally, all patients treated with ranibizumab are registered. Certainly this is a very difficult target to achieve but we will try to have as many patients as possible on the register. The program is in all different continents and we have centers all over the world that will be able to include patients treated with ranibizumab for different indications. At the moment, we already have more than 4400 patients included in the study and this will be a retrospective analysis of those patients already treated with ranibizumab but now we are starting a second phase where prospective patients will be considered for this kind of treatment.

  《国际眼科时讯》:您能给我们简单介绍一下LUMINOUS目前的研究情况吗?
  Dr Bandello: LUMINOUS是一项流行病学研究,我们的目标是对所有不同雷珠单抗适应证且接受过雷珠单抗治疗的患者进行登记。理想中,所有接受雷珠单抗治疗的患者全部进行登记。当然,这是一项很难达到的目标,但是我们将会登记尽可能多的患者。这一项目在不同大洲均在进行,我们在世界上许多地方设有研究中心,这能够促进我们对不同适应证的患者进行登记。目前,我们研究中已登记在册的患者超过4400例,这将会是一项针对接受过雷珠单抗治疗患者的回顾性分析,现在,我们正在开始第二阶段的研究,对于之后的患者将会考虑采用此种方式。

  <International OphthalmologyTimes>:  What challenges do you face in the LUMINOUS trial in order to recruit so many patients? As you said, you currently have almost 4500 patients in the study. What is the rate of d rop-outs?
  Dr Bandello: The d rop-out rate was relatively low. We had some d rop-outs but it was not that important. What is already available from the data we have in the system is that the modalities of treatment for patients with different indications are a little bit different from the modalities that are known from the studies. In the studies, the protocols were significantly different from what we are finding in the patients included in the register up to now.

  《国际眼科时讯》:在LUMINOUS研究中,为了招募如此多的患者,将会面临哪些挑战?如您所说,目前研究中已经招募了将近4500例患者,那么脱失率是多少?
  Dr Bandello:脱失率相对较低,我们存在一些患者脱失,但这并不是那么重要。目前,我们研究系统中的数据显示,不同适应证患者的临床治疗方式与课题研究中的治疗方式存在一定差别。研究中的治疗方案与我们登记在册的患者所接受的治疗方案存在显著差异。

  <International OphthalmologyTimes>: The mean number of ranibizumab injections ranged from 4.3 to 5.7 over 12 months. Does that mean all patients received PRN treatment?
  Dr Bandello: No it doesn’t mean that all patients received PRN treatment but it means that the number of treatments is relatively low compared to what we know is the best strategy for our patients.

  《国际眼科时讯》:一年内患者接受雷珠单抗注射治疗的平均次数大概在4.3至5.7之间,这是否意味着所有的患者都是接受按需治疗?
  Dr Bandello:这并不是意味着所有患者均接受按需治疗,而是意味着与我们目前所认为的最好的治疗策略相比,患者接受治疗的次数相对较少。

  <International OphthalmologyTimes>:  Is there any detail about PRN regimens?
  Dr Bandello: The PRN treatment is different in different countries on the basis of labeling. For example, in Europe, the label states three injections given monthly and then PRN treatment based on visual acuity. A d rop in visual acuity associated or not with OCT changes was justification for further treatment. This is how the drug is labeled but we must admit that sometimes the modalities of treatment are a little different.

  《国际眼科时讯》:关于按需治疗方式有什么细节问题吗?
  Dr Bandello:按需治疗在不同国家因药品说明书标识不同而存在差异,例如,在欧洲药品标识声明,每月注射,连续3次后依据视力情况进行按需治疗。视力下降伴或者不伴有OCT改变均可进行进一步治疗。这是药物说明书标识所指导的,但是我们不得不承认有时在临床中的治疗形式会有些不同。

  <International OphthalmologyTimes>: With this injection number, did patients maintain a visual gain?
  Dr Bandello: I must say that the visual acuity was more-or-less maintained in the data that we have to date, despite this low number.

  《国际眼科时讯》:依照这种注射次数,患者能够保持视力提高吗?
  Dr Bandello:我必须说,尽管迄今为止我们的数据显示患者接受注射治疗的次数较低,但是或多或少都能够维持视力。

  <International OphthalmologyTimes>:  In your poster’s conclusion, it was stated that “a low number of ranibizumab injections in nAMB during the first year was noted.” What factors may have affected this low number?
  Dr Bandello: It is difficult to say if there are common factors for all the different countries and different realities. What I can imagine is that sometimes the number of injections is reduced because of difficulties with logistics such as patients that are far away from the center or a great number of patients who have to be treated in a small center. These reasons may justify why the number of injections is a little lower than what is needed.

  《国际眼科时讯》:在您壁报的结论中指出,在nAMD研究中,患者第一年接受雷珠单抗注射治疗的次数很低。影响注射次数低的可能因素有哪些?
  Dr Bandello:在不同国家及不同实际情况下,很难说是否存在一些共同的原因。我想,有时注射次数减少可能是存在运筹上的困难,例如一些患者离治疗中心较远或者在小治疗中心需要面对大量的治疗患者。这些原因或许能够解释患者接受的注射治疗次数比需要的少。
 


分享 |
 
相关搜索
AMD 
 延伸阅读
【本文章已有0 人评论,点击查看。】

用户评论

查看全部评论
推荐视频 more<<  

作者资源

友情链接

国际循环网

国际糖尿病网

国际肝病网

肿瘤瞭望网

中国医师协会眼科医师分会

国际眼科学和视光学学术会议
设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际眼科时讯( www.iophthal.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
国际眼科 版权所有 京ICP备18007927号-2   京公网安备 11010502033360号  互联网药品信息服务资格证书编号(京)-非经营性2020-0017
 2011-2021 www.iophthal.com All Rights Reserved